JP2020503295A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020503295A5 JP2020503295A5 JP2019531735A JP2019531735A JP2020503295A5 JP 2020503295 A5 JP2020503295 A5 JP 2020503295A5 JP 2019531735 A JP2019531735 A JP 2019531735A JP 2019531735 A JP2019531735 A JP 2019531735A JP 2020503295 A5 JP2020503295 A5 JP 2020503295A5
- Authority
- JP
- Japan
- Prior art keywords
- hepta
- thia
- azabicyclo
- ethynyl
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 47
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 33
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 33
- -1 2-propynyloxy Chemical group 0.000 claims 32
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 23
- 150000003839 salts Chemical class 0.000 claims 23
- GZPHSAQLYPIAIN-UHFFFAOYSA-N 3-pyridinecarbonitrile Chemical compound N#CC1=CC=CN=C1 GZPHSAQLYPIAIN-UHFFFAOYSA-N 0.000 claims 16
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 206010012289 Dementia Diseases 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- SSXJHQZOHUYEGD-UHFFFAOYSA-N 3-Methoxynobiletin Chemical compound C1=C(OC)C(OC)=CC=C1C1=C(OC)C(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 SSXJHQZOHUYEGD-UHFFFAOYSA-N 0.000 claims 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 208000010877 cognitive disease Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 4
- 125000001786 isothiazolyl group Chemical group 0.000 claims 4
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- OADSMBXFJIAAJA-UHFFFAOYSA-N oct-4-enamide Chemical compound CCCC=CCCC(N)=O OADSMBXFJIAAJA-UHFFFAOYSA-N 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 4
- 125000000335 thiazolyl group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- WRIHTLGFUKBBKQ-CEAUUGKZSA-N (1S,5S)-5-[5-[2-(5-chloro-3-methylpyridin-2-yl)ethynyl]-2-fluorophenyl]-1-(methoxymethyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-3-amine Chemical compound ClC=1C=C(C(=NC=1)C#CC=1C=CC(=C(C=1)[C@]1(N=C(S[C@]2(CC12)COC)N)C)F)C WRIHTLGFUKBBKQ-CEAUUGKZSA-N 0.000 claims 2
- OMEMOIMHKXXIAX-AGILITTLSA-N (1S,5S,6S)-1,5-bis(fluoromethyl)-5-[2-fluoro-5-[2-[5-(1,3-oxazol-2-ylmethoxy)pyridin-2-yl]ethynyl]phenyl]-2-thia-4-azabicyclo[4.1.0]hept-3-en-3-amine Chemical compound FC1=C(C=C(C=C1)C#CC1=NC=C(C=C1)OCC=1OC=CN=1)[C@]1(N=C(S[C@]2(C[C@@H]12)CF)N)CF OMEMOIMHKXXIAX-AGILITTLSA-N 0.000 claims 2
- RAHDYDYNSIAFMG-FDJWOJMMSA-N (1S,5S,6S)-3-amino-5-[2-fluoro-5-[2-[3-methyl-5-(1,3-oxazol-2-ylmethoxy)pyridin-2-yl]ethynyl]phenyl]-N,N,5-trimethyl-2-thia-4-azabicyclo[4.1.0]hept-3-ene-1-carboxamide Chemical compound NC=1S[C@]2(C[C@H]2[C@@](N=1)(C)C1=C(C=CC(=C1)C#CC1=NC=C(C=C1C)OCC=1OC=CN=1)F)C(=O)N(C)C RAHDYDYNSIAFMG-FDJWOJMMSA-N 0.000 claims 2
- CBYOFAWUWAYPKP-KSEOMHKRSA-N (1S,5S,6S)-3-amino-5-[5-[2-(5-cyano-3-methylpyridin-2-yl)ethynyl]-2-fluorophenyl]-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-ene-1-carbonitrile Chemical compound NC=1S[C@]2(C[C@H]2[C@@](N=1)(C)C1=C(C=CC(=C1)C#CC1=NC=C(C=C1C)C#N)F)C#N CBYOFAWUWAYPKP-KSEOMHKRSA-N 0.000 claims 2
- KEYGOCWGASLCFN-ZTCOLXNVSA-N (1S,5S,6S)-3-amino-5-[5-[2-(5-cyano-3-methylpyridin-2-yl)ethynyl]-2-fluorophenyl]-N,N,5-trimethyl-2-thia-4-azabicyclo[4.1.0]hept-3-ene-1-carboxamide Chemical compound NC=1S[C@]2(C[C@H]2[C@@](N=1)(C)C1=C(C=CC(=C1)C#CC1=NC=C(C=C1C)C#N)F)C(=O)N(C)C KEYGOCWGASLCFN-ZTCOLXNVSA-N 0.000 claims 2
- FAQNBNVGHSOMNY-MISYRCLQSA-N (1S,5S,6S)-5-[5-[2-(5-chloropyridin-2-yl)ethynyl]-2-fluorophenyl]-1,5-bis(fluoromethyl)-2-thia-4-azabicyclo[4.1.0]hept-3-en-3-amine Chemical compound ClC=1C=CC(=NC=1)C#CC=1C=CC(=C(C=1)[C@]1(N=C(S[C@]2(C[C@@H]12)CF)N)CF)F FAQNBNVGHSOMNY-MISYRCLQSA-N 0.000 claims 2
- AOKKWUDSGZAXHM-HSWNYDEUSA-N (E)-3-[(1R,5S,6S)-3-amino-5-[5-[2-(5-cyanopyridin-2-yl)ethynyl]-2-fluorophenyl]-5-(fluoromethyl)-2-thia-4-azabicyclo[4.1.0]hept-3-en-1-yl]-N,N-dimethylprop-2-enamide Chemical compound NC=1S[C@]2(C[C@H]2[C@@](N=1)(CF)C1=C(C=CC(=C1)C#CC1=NC=C(C=C1)C#N)F)/C=C/C(=O)N(C)C AOKKWUDSGZAXHM-HSWNYDEUSA-N 0.000 claims 2
- XWXPRCDFFCVMNT-UHFFFAOYSA-N 1,3-thiazole-5-carbonitrile Chemical compound N#CC1=CN=CS1 XWXPRCDFFCVMNT-UHFFFAOYSA-N 0.000 claims 2
- AFTWTRHAYWBSST-ONGRUHMKSA-N 2-[2-[3-[(1R,5S,6S)-3-amino-5-(fluoromethyl)-1-[(E)-3-morpholin-4-yl-3-oxoprop-1-enyl]-2-thia-4-azabicyclo[4.1.0]hept-3-en-5-yl]-4-fluorophenyl]ethynyl]pyrimidine-5-carbonitrile Chemical compound NC1=N[C@@](CF)([C@@H]2C[C@@]2(S1)\C=C\C(=O)N1CCOCC1)c1cc(ccc1F)C#Cc1ncc(cn1)C#N AFTWTRHAYWBSST-ONGRUHMKSA-N 0.000 claims 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- HKMWURYHQXDLAG-NVAWJBEOSA-N 4-[2-[3-[(1R,5S,6S)-3-amino-5-(fluoromethyl)-1-[(E)-3-morpholin-4-yl-3-oxoprop-1-enyl]-2-thia-4-azabicyclo[4.1.0]hept-3-en-5-yl]-4-fluorophenyl]ethynyl]benzonitrile Chemical compound NC1=N[C@@](CF)([C@@H]2C[C@@]2(S1)\C=C\C(=O)N1CCOCC1)c1cc(ccc1F)C#Cc1ccc(cc1)C#N HKMWURYHQXDLAG-NVAWJBEOSA-N 0.000 claims 2
- RJOFQCKQEMAZEM-BAGYTPMASA-N 6-[2-[3-[(1R,5S,6S)-3-amino-1-(cyanomethyl)-5-(fluoromethyl)-2-thia-4-azabicyclo[4.1.0]hept-3-en-5-yl]-4-fluorophenyl]ethynyl]pyridine-3-carbonitrile Chemical compound NC=1S[C@]2(C[C@H]2[C@@](N=1)(CF)C=1C=C(C=CC=1F)C#CC1=NC=C(C#N)C=C1)CC#N RJOFQCKQEMAZEM-BAGYTPMASA-N 0.000 claims 2
- KJOFKJHARIZLRZ-ALCSNEQFSA-N 6-[2-[3-[(1R,5S,6S)-3-amino-5-(fluoromethyl)-1-[(E)-3-morpholin-4-yl-3-oxoprop-1-enyl]-2-thia-4-azabicyclo[4.1.0]hept-3-en-5-yl]-4-fluorophenyl]ethynyl]-5-methylpyridine-3-carbonitrile Chemical compound NC=1S[C@]2(C[C@H]2[C@@](N=1)(CF)C=1C=C(C=CC=1F)C#CC1=NC=C(C#N)C=C1C)\C=C\C(=O)N1CCOCC1 KJOFKJHARIZLRZ-ALCSNEQFSA-N 0.000 claims 2
- FRVCLHJFWPHQDO-ACYVMRIUSA-N 6-[2-[3-[(1R,5S,6S)-3-amino-5-(fluoromethyl)-1-[(E)-3-morpholin-4-yl-3-oxoprop-1-enyl]-2-thia-4-azabicyclo[4.1.0]hept-3-en-5-yl]-4-fluorophenyl]ethynyl]pyridine-3-carbonitrile Chemical compound NC=1S[C@]2(C[C@H]2[C@@](N=1)(CF)C=1C=C(C=CC=1F)C#CC1=NC=C(C#N)C=C1)\C=C\C(=O)N1CCOCC1 FRVCLHJFWPHQDO-ACYVMRIUSA-N 0.000 claims 2
- MYTZXYYCRAMPEU-PWIZWCRZSA-N 6-[2-[5-[(1S,5S,6S)-3-amino-1-(fluoromethyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-5-yl]-6-fluoropyridin-3-yl]ethynyl]pyridine-3-carbonitrile Chemical compound NC=1S[C@]2(C[C@H]2[C@@](N=1)(C)C=1C=C(C=NC=1F)C#CC1=NC=C(C#N)C=C1)CF MYTZXYYCRAMPEU-PWIZWCRZSA-N 0.000 claims 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims 2
- 201000010374 Down Syndrome Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims 2
- 206010002022 amyloidosis Diseases 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 230000002490 cerebral effect Effects 0.000 claims 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- PMSVVUSIPKHUMT-UHFFFAOYSA-N cyanopyrazine Chemical compound N#CC1=CN=CC=N1 PMSVVUSIPKHUMT-UHFFFAOYSA-N 0.000 claims 2
- YGUTWCADDMAUOD-UHFFFAOYSA-N hept-3-en-3-amine Chemical compound CCCC=C(N)CC YGUTWCADDMAUOD-UHFFFAOYSA-N 0.000 claims 2
- 230000007505 plaque formation Effects 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- CFWGZKJFJHRPLR-XKQJLSEDSA-N (1S,5S,6S)-3-amino-5-(5-ethynyl-2-fluorophenyl)-N,N,5-trimethyl-2-thia-4-azabicyclo[4.1.0]hept-3-ene-1-carboxamide Chemical compound NC=1S[C@]2(C[C@H]2[C@@](N=1)(C)C1=C(C=CC(=C1)C#C)F)C(=O)N(C)C CFWGZKJFJHRPLR-XKQJLSEDSA-N 0.000 claims 1
- MOAJIFLFRHPNCU-GPUOULLFSA-N (1S,5S,6S)-3-amino-5-[2-fluoro-5-[2-(5-prop-2-ynoxypyridin-2-yl)ethynyl]phenyl]-N,N,5-trimethyl-2-thia-4-azabicyclo[4.1.0]hept-3-ene-1-carboxamide Chemical compound NC=1S[C@]2(C[C@H]2[C@@](N=1)(C)C1=C(C=CC(=C1)C#CC1=NC=C(C=C1)OCC#C)F)C(=O)N(C)C MOAJIFLFRHPNCU-GPUOULLFSA-N 0.000 claims 1
- ASCVRCHPGUMCIB-ZTCOLXNVSA-N (1S,5S,6S)-3-amino-5-[5-[2-(5-cyano-3-methylpyridin-2-yl)ethynyl]-2-fluorophenyl]-5-(fluoromethyl)-N,N-dimethyl-2-thia-4-azabicyclo[4.1.0]hept-3-ene-1-carboxamide Chemical compound NC=1S[C@]2(C[C@H]2[C@@](N=1)(CF)C1=C(C=CC(=C1)C#CC1=NC=C(C=C1C)C#N)F)C(=O)N(C)C ASCVRCHPGUMCIB-ZTCOLXNVSA-N 0.000 claims 1
- MLJGESCVVGWMSL-MISYRCLQSA-N (1S,5S,6S)-5-[5-[2-(4-chloropyridin-2-yl)ethynyl]-2-fluorophenyl]-1,5-bis(fluoromethyl)-2-thia-4-azabicyclo[4.1.0]hept-3-en-3-amine Chemical compound ClC1=CC(=NC=C1)C#CC=1C=CC(=C(C=1)[C@]1(N=C(S[C@]2(C[C@@H]12)CF)N)CF)F MLJGESCVVGWMSL-MISYRCLQSA-N 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- UUCVLVXHCQKZPD-ZEBAXETDSA-N (E)-3-[(1R,5S,6S)-3-amino-5-[5-[2-(5-chloropyrimidin-2-yl)ethynyl]-2-fluorophenyl]-5-(fluoromethyl)-2-thia-4-azabicyclo[4.1.0]hept-3-en-1-yl]-1-morpholin-4-ylprop-2-en-1-one Chemical compound NC=1S[C@]2(C[C@H]2[C@@](N=1)(CF)C1=C(C=CC(=C1)C#CC1=NC=C(C=N1)Cl)F)/C=C/C(=O)N1CCOCC1 UUCVLVXHCQKZPD-ZEBAXETDSA-N 0.000 claims 1
- NGFGTPHIPOZBPD-HZQXDJCGSA-N 6-[2-[3-[(1R,5S,6S)-3-amino-5-(fluoromethyl)-1-[(E)-3-morpholin-4-yl-3-oxoprop-1-enyl]-2-thia-4-azabicyclo[4.1.0]hept-3-en-5-yl]-4-fluorophenyl]ethynyl]-5-fluoropyridine-3-carbonitrile Chemical compound NC=1S[C@]2(C[C@H]2[C@@](N=1)(CF)C=1C=C(C=CC=1F)C#CC1=NC=C(C#N)C=C1F)\C=C\C(=O)N1CCOCC1 NGFGTPHIPOZBPD-HZQXDJCGSA-N 0.000 claims 1
- KTNWHHMLWOVZTA-RQFYCUQDSA-N 6-[2-[5-[(1S,5S)-3-amino-5-methyl-1-(pyrrolidine-1-carbonyl)-2-thia-4-azabicyclo[4.1.0]hept-3-en-5-yl]-6-fluoropyridin-3-yl]ethynyl]-5-methylpyridine-3-carbonitrile Chemical compound NC=1S[C@]2(CC2[C@@](N=1)(C)C=1C=C(C=NC=1F)C#CC1=NC=C(C#N)C=C1C)C(=O)N1CCCC1 KTNWHHMLWOVZTA-RQFYCUQDSA-N 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 206010048327 Supranuclear palsy Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662434721P | 2016-12-15 | 2016-12-15 | |
| US62/434,721 | 2016-12-15 | ||
| PCT/US2017/066184 WO2018112086A1 (en) | 2016-12-15 | 2017-12-13 | Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020503295A JP2020503295A (ja) | 2020-01-30 |
| JP2020503295A5 true JP2020503295A5 (enExample) | 2021-01-28 |
| JP7159161B2 JP7159161B2 (ja) | 2022-10-24 |
Family
ID=60888747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531735A Active JP7159161B2 (ja) | 2016-12-15 | 2017-12-13 | β－セクレターゼ阻害剤としてのシクロプロピル縮合チアジン誘導体および使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10889581B2 (enExample) |
| EP (1) | EP3555085B1 (enExample) |
| JP (1) | JP7159161B2 (enExample) |
| AU (1) | AU2017378316B2 (enExample) |
| MX (1) | MX386618B (enExample) |
| WO (1) | WO2018112086A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX388697B (es) | 2016-12-15 | 2025-03-20 | Amgen Inc | Derivados de tiazina como inhibidores de beta-secretasa y metodos de uso. |
| AU2017376441B2 (en) | 2016-12-15 | 2021-10-14 | Amgen Inc. | Oxazine derivatives as beta-secretase inhibitors and methods of use |
| MX386618B (es) | 2016-12-15 | 2025-03-19 | Amgen Inc | Derivados de tiazina condensados con ciclopropilo como inhibidores de beta-secretasa y métodos de uso. |
| MX387729B (es) | 2016-12-15 | 2025-03-18 | Amgen Inc | Derivados de dióxido de 1,4-tiazina y dióxido 1,2,4-tiadiazina como inhibidores de beta-secretasa y métodos de uso. |
| AU2017376445B2 (en) | 2016-12-15 | 2021-09-30 | Amgen Inc. | Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5441870A (en) | 1992-04-15 | 1995-08-15 | Athena Neurosciences, Inc. | Methods for monitoring cellular processing of β-amyloid precursor protein |
| SI9300303A (en) | 1993-06-08 | 1994-12-31 | Krka Tovarna Zdravil | Process for isolation of hypolipemic effective substance |
| JPH11507538A (ja) | 1995-06-07 | 1999-07-06 | アテナ ニューロサイエンシズ インコーポレイティド | β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ |
| ES2318902T3 (es) | 1998-09-24 | 2009-05-01 | PHARMACIA & UPJOHN COMPANY LLC | Secretasa en la enfermedad del alzheimer. |
| ES2537898T3 (es) | 2005-10-25 | 2015-06-15 | Shionogi & Co., Ltd. | Derivados de aminotiazolidina y aminotetrahidrotiazepina como inhibidores de BACE 1 |
| AU2008245082B8 (en) | 2007-04-24 | 2012-09-13 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives substituted with a cyclic group |
| EP2151435A4 (en) | 2007-04-24 | 2011-09-14 | Shionogi & Co | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| BRPI0906962B8 (pt) | 2008-01-18 | 2021-05-25 | Eisai R&D Man Co Ltd | composto de aminodiidrotiazina fundido |
| TWI431004B (zh) | 2008-05-02 | 2014-03-21 | Lilly Co Eli | Ｂａｃｅ抑制劑 |
| US8637504B2 (en) | 2008-06-13 | 2014-01-28 | Shionogi & Co., Ltd. | Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity |
| WO2010013302A1 (ja) | 2008-07-28 | 2010-02-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | スピロアミノジヒドロチアジン誘導体 |
| AU2009277485B2 (en) | 2008-07-28 | 2013-05-02 | Eisai R&D Management Co., Ltd. | Spiroaminodihydrothiazine derivatives |
| KR20110076965A (ko) | 2008-09-30 | 2011-07-06 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 신규한 축합 아미노 디하이드로티아진 유도체 |
| AR077277A1 (es) | 2009-07-09 | 2011-08-17 | Lilly Co Eli | Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer |
| GB0912778D0 (en) | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydro-oxazine derivatives |
| US20110065695A1 (en) | 2009-09-11 | 2011-03-17 | Jeremy Beauchamp | Use of aminodihydrothiazines for the treatment or prevention of diabetes |
| UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
| CN102686584A (zh) | 2009-11-13 | 2012-09-19 | 盐野义制药株式会社 | 具有氨基连接基的氨基噻嗪或氨基噁嗪衍生物 |
| US20120245154A1 (en) | 2009-12-09 | 2012-09-27 | Shionogi & Co., Ltd. | Substituted aminothiazine derivative |
| RU2012129168A (ru) | 2009-12-11 | 2014-01-20 | Сионоги Энд Ко. Лтд. | Производные оксазина |
| UA103272C2 (uk) | 2009-12-11 | 2013-09-25 | Ф. Хоффманн-Ля Рош Аг | 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2 |
| CN103429589A (zh) | 2011-01-12 | 2013-12-04 | 诺瓦提斯公司 | 噁嗪衍生物及其在治疗神经障碍中的用途 |
| KR101569260B1 (ko) | 2011-01-13 | 2015-11-13 | 노파르티스 아게 | 신규 헤테로시클릭 유도체 및 신경계 장애의 치료에서의 그의 용도 |
| GB201101140D0 (en) | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
| GB201101139D0 (en) | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
| WO2012138734A1 (en) | 2011-04-07 | 2012-10-11 | Merck Sharp & Dohme Corp. | C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| BR112013026341A2 (pt) | 2011-04-13 | 2019-09-24 | Merck Sharp & Dohe Corp. | composto, composição farmacêutica, e, método para tratar, prevenir e/ou atrasar o início de uma doença ou patologia |
| WO2012147762A1 (ja) | 2011-04-26 | 2012-11-01 | 塩野義製薬株式会社 | ピリジン誘導体およびそれを含有するｂａｃｅ１阻害剤 |
| EP2517898A1 (de) | 2011-04-29 | 2012-10-31 | Lanxess Deutschland GmbH | Kieselsäurehaltige Kautschukmischungen mit schwefelhaltigen Additiven |
| US8785436B2 (en) | 2011-05-16 | 2014-07-22 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE 1 and/or BACE2 inhibitors |
| US8604024B2 (en) | 2011-05-24 | 2013-12-10 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
| TW201302763A (zh) | 2011-05-24 | 2013-01-16 | 必治妥美雅史谷比公司 | 用於減少β－類澱粉產生之化合物 |
| US8927535B2 (en) | 2011-07-06 | 2015-01-06 | Hoffman-La Roche Inc. | Cyclopropyl-fused-1,3-thiazepines as BACE1 and/or BACE2 inhibitors |
| RU2014111055A (ru) | 2011-08-22 | 2015-09-27 | Мерк Шарп И Доум Корп. | 2-спирозамещенные иминотиазины и их моно- и диоксиды в качестве ингибиторов bace, композиции и их применение |
| UY34278A (es) | 2011-08-25 | 2013-04-05 | Novartis Ag | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades |
| WO2013030713A1 (en) | 2011-08-31 | 2013-03-07 | Pfizer Inc. | Hexahydropyrano [3,4-d][1,3] thiazin-2-amine compounds |
| US9493485B2 (en) | 2012-03-20 | 2016-11-15 | Imago Pharmaceuticals, Inc. | Spirocyclic dihydro-thiazine and dihydro-oxazine BACE inhibitors, and compositions and uses thereof |
| WO2013164730A1 (en) | 2012-05-04 | 2013-11-07 | Pfizer Inc. | Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin- 2 -amine compounds as inhibitors of app, bace1 and bace 2. |
| WO2013182638A1 (en) | 2012-06-08 | 2013-12-12 | H. Lundbeck A/S | 2 -aminothiazinylheteroaryls as bace1 inhibitors for the treatment alzheimer's disease |
| GB201212871D0 (en) | 2012-07-20 | 2012-09-05 | Eisai Ltd | Novel compounds |
| JP2015529239A (ja) | 2012-09-20 | 2015-10-05 | ファイザー・インク | アルキル置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物 |
| EP2908825B1 (en) | 2012-10-17 | 2018-04-18 | Merck Sharp & Dohme Corp. | Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| WO2014062553A1 (en) | 2012-10-17 | 2014-04-24 | Merck Sharp & Dohme Corp. | Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| JP2016501827A (ja) | 2012-10-24 | 2016-01-21 | 塩野義製薬株式会社 | Ｂａｃｅ１阻害作用を有するジヒドロオキサジンまたはオキサゼピン誘導体 |
| CA2886507C (en) | 2012-10-26 | 2016-09-20 | Eli Lilly And Company | Bace inhibitors |
| US9447085B2 (en) | 2012-12-14 | 2016-09-20 | Merck Sharp & Dohme Corp. | Iminothiadiazine dioxides containing a thioamide, amidine, or amide oxime group as BACE inhibitors, compositions, and their use |
| CA2893333C (en) | 2012-12-19 | 2017-10-24 | Pfizer Inc. | Carbocyclic-and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| EP2935256B1 (en) | 2012-12-19 | 2018-01-24 | Bristol-Myers Squibb Company | 4,6-diarylaminothiazines as bace1 inhibitors and their use for the reduction of beta-amyloid production |
| CN104870000A (zh) | 2012-12-20 | 2015-08-26 | 默沙东公司 | 作为bace抑制剂的c5,c6氧杂环稠合的亚胺基噻嗪二氧化物化合物,组合物及其用途 |
| US9580396B2 (en) | 2012-12-21 | 2017-02-28 | Merck Sharp & Dohme Corp. | C6-spiro iminothiadiazine dioxides as BACE inhibitors, compositions, and their use |
| CN104968660A (zh) | 2013-01-22 | 2015-10-07 | 霍夫曼-拉罗奇有限公司 | 作为bace1抑制剂的氟-[1,3]噁嗪类化合物 |
| AU2014223334C1 (en) | 2013-03-01 | 2018-10-18 | Amgen Inc. | Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| EP2964644B1 (en) | 2013-03-08 | 2018-12-26 | Amgen, Inc. | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| TWI593692B (zh) | 2013-03-12 | 2017-08-01 | 美國禮來大藥廠 | 四氫吡咯并噻嗪化合物 |
| MX381482B (es) * | 2014-08-08 | 2025-03-12 | Amgen Inc | Compuestos de tiazin-2-amina fusionados con ciclopropilo como inhibidores de beta-secretasa y metodos de uso. |
| JP6765681B2 (ja) | 2015-04-21 | 2020-10-07 | オールジェネシス バイオセラピューティクス インコーポレイテッド | Ｂａｃｅ１阻害剤としての化合物およびそれらの使用 |
| US10246429B2 (en) | 2015-08-06 | 2019-04-02 | Amgen Inc. | Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| AU2017376441B2 (en) | 2016-12-15 | 2021-10-14 | Amgen Inc. | Oxazine derivatives as beta-secretase inhibitors and methods of use |
| MX386618B (es) | 2016-12-15 | 2025-03-19 | Amgen Inc | Derivados de tiazina condensados con ciclopropilo como inhibidores de beta-secretasa y métodos de uso. |
| AU2017376445B2 (en) | 2016-12-15 | 2021-09-30 | Amgen Inc. | Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use |
| MX388697B (es) | 2016-12-15 | 2025-03-20 | Amgen Inc | Derivados de tiazina como inhibidores de beta-secretasa y metodos de uso. |
| MX387729B (es) | 2016-12-15 | 2025-03-18 | Amgen Inc | Derivados de dióxido de 1,4-tiazina y dióxido 1,2,4-tiadiazina como inhibidores de beta-secretasa y métodos de uso. |
-
2017
- 2017-12-13 MX MX2019007103A patent/MX386618B/es unknown
- 2017-12-13 EP EP17822987.8A patent/EP3555085B1/en active Active
- 2017-12-13 JP JP2019531735A patent/JP7159161B2/ja active Active
- 2017-12-13 US US16/466,199 patent/US10889581B2/en active Active
- 2017-12-13 AU AU2017378316A patent/AU2017378316B2/en active Active
- 2017-12-13 WO PCT/US2017/066184 patent/WO2018112086A1/en not_active Ceased